Login to Your Account



Other News To Note


Tuesday, April 3, 2012
• Inovio Pharmaceuticals Inc., of Blue Bell, Pa., said it received a Department of Defense (DoD) Small Business Innovation Research grant to advance the development of a low-cost, non-invasive surface electroporation delivery device and test its use in combination with Inovio's synthetic DNA vaccines against viruses with bioterrorism potential, including hanta, puumala, arenavirus and pandemic influenza.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription